Konrad, Matthias
Rinscheid, Andreas
Wienand, Georgine
Nittbaur, Bernd
Wester, Hans-Jürgen
Janzen, Tilman
Lapa, Constantin
Pfob, Christian Helmut
Schottelius, Margret http://orcid.org/0000-0002-1928-6913
Funding for this research was provided by:
University of Lausanne
Article History
Received: 2 June 2023
Accepted: 5 August 2023
First Online: 19 August 2023
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki or comparable ethical standards. All animal experiments were conducted in accordance with general animal welfare regulations in Germany and the institutional guidelines for the care and use of animals. The use of [<sup>99m</sup>Tc]Tc-PentixaTec was in compliance with the German Medicinal Products Act, AMG §13 No 2b and reported to the regulatory office (Regierung von Oberbayern). The analysis of patient data was approved by the Ethics Committee of Ludwig-Maximilians Universität München (permit 22–0850).
: Informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent for publication of the images in Figs. InternalRef removed and InternalRef removed.
: M.K., M.S., and H.J.W. are listed as inventors on the patent on PentixaTec and related compounds (EP21157225.0). M.S. and C.L. are scientific advisors for PentixaPharm GmbH, the exclusive license holder for PentixaTec.